



MEMORANDUM OF UNDERSTANDING 2020-21

BETWEEN
DEPARTMENT OF BIOTECHNOLOGY
MINISTRY OF SCIENCE & TECHNOLOGY
GOVERNMENT OF INDIA

AND

**BIOTECHNOLOGY INDUSTRY RESEARCH
ASSISTANCE COUNCIL (BIRAC)**
A GOVERNMENT OF INDIA ENTERPRISE



MEMORANDUM OF UNDERSTANDING 2020-2021

BETWEEN

DEPARTMENT OF BIOTECHNOLOGY

(MINISTRY OF SCIENCE & TECHNOLOGY)

AND

**BIOTECHNOLOGY INDUSTRY RESEARCH ASSISTANCE
COUNCIL (BIRAC)**

(A GOVERNMENT OF INDIA ENTERPRISE)





INDEX

PART I	BACKGROUND	1
PART II	MISSION, VISION AND OBJECTIVES OF BIRAC	2
PART III	BRIEF ABOUT THE CPSE	4
PART IV	PERFORMANCE ASSESSMENT TARGETS AND THEIR DETERMINATION	6
PART V	SELF-DECLARATION/CERTIFICATION BY CPSE	8



**MEMORANDUM OF UNDERSTANDING
2020-2021**

BETWEEN

DEPARTMENT OF BIOTECHNOLOGY, MINISTRY OF SCIENCE & TECHNOLOGY

AND

BIOTECHNOLOGY INDUSTRY RESEARCH ASSISTANCE COUNCIL (BIRAC)

I. BACKGROUND

Biotechnology Industry Assistance Council (BIRAC) is a unique organization, the first of its kind set up in the country for promoting and mentoring innovation research for affordable product development. Recognizing the need for promoting industry partnership to take research lead through the translational phase to product development, the Department of Biotechnology, Ministry of Science and Technology, Government of India had made a very significant announcement in the National Biotechnology Development Strategy in 2007, stating that 30% of its budget will be invested into Public Private Partnership and a separate organization, Biotechnology Industry Research Assistance Council (BIRAC) would be set up to implement and execute this. With the approval of the Cabinet, Biotechnology Industry Research Assistance Council (BIRAC) was set up on 20th March, 2012 as a public sector, 'Not – for-Profit' Section 8 company under the Companies Act, 2013. BIRAC, a Schedule B CPSE, is an interface agency of the Department of Biotechnology, Ministry of Science & Technology, and has the mandate of fostering and nurturing the biotech enterprises specially start-ups and SMEs for enhancing their innovation research capacities and promoting affordable product development. BIRAC supports Industry-Academia interaction, serves as a single window for the emerging biotech industry, helps establish connectivity with professional and institutional networks and provides financial support for quality innovation targeted at affordable solutions and product development.

BIRAC is working towards providing enabling support and empowering the entire innovation ecosystem and today more than 1000 start-ups and entrepreneurs and 500 companies – large, small and medium are a part of BIRAC's Innovators network. Biotechnology Industry Research Assistance Council (BIRAC) has its registered office in the National Capital Territory of Delhi with an authorized capital of Rs. 1 crore divided into 10,000 equity shares of Rs. 1,000 each.

BIRAC has positioned itself as a dynamic organization nurturing and promoting innovation led research and today it plays an important role as a facilitator and not merely a service provider. BIRAC applied unique methodologies for nurturing high risk projects of societal relevance with potential for commercialization.

II. MISSION, VISION AND OBJECTIVES

1 MISSION

The mission of BIRAC is to facilitate overall growth of the biotech sector by mentoring and supporting generation and translation of innovative ideas, products and processes into viable bio-enterprises, enabling creation of biotech products and services and encouraging entrepreneurship.

2 VISION

The vision of BIRAC is to stimulate, foster and enhance the strategic research and innovation capabilities of the Indian biotech industry, particularly start-ups & SMEs to make India globally competitive in biotech innovation and entrepreneurship to create affordable products and provide services for addressing the problems of the larger section of society.

3 OBJECTIVES

The objective of BIRAC is to work as Development Agency in the field of biotechnology and address the national needs of health, energy, agriculture through bottom up competitive grant approach of through top down product development programmes. Various aspects of operation of BIRAC are as under: -

- (1) To encourage young minds with new ideas, supporting early stage research for proof of concept, technology validation, and partner with industry for high risk discovery led innovation research.
- (2) To take discovery forward to product development through Biotechnology Ignition Grant (BIG), Biotechnology Industry Partnership Programme (BIPP), Small Business Innovation Research Initiative (SBIRI), Contract Research Scheme (CRS), Bio Incubator Support (BioNEST) and support Product Innovation and Commercialization for addressing Grand Challenges of national relevance.
- (3) To provide services for Entrepreneurial Development such as IP services, Technology Transfer and Acquisition, Legal and Contracts, Policy and Analysis and Mentoring & Capacity Building.
- (4) To encourage and evolve new forms of governance structure for motivating academia-industry partnership for achieving the highest level of excellence in promoting and nurturing the biotech sector.

4. The quantitative parameters with reference to the objectives are as under:

- (1) New Technologies brought to market.
- (2) New start-ups supported and scaled up.
- (3) Small and medium enterprises strengthened.

-
- (4) Investments made on discovery and innovation research. These will include high risk-high return and high risk-low return but with high social impact.
 - (5) Investments recovered in terms of loan repayments, royalty, new products launched, new technologies, IP generated and protected, IP commercialized.
 - (6) Affordable products developed.
 - (7) New models of partnership-academia, industry, public, private, national and international.

III Brief about the CPSE

1.	Name of the CPSE	Biotechnology Industry Research Assistance Council
2.	Status (Please tick): As per DPE guidelines	None
3.	Schedule of the CPSE (Please tick)	Schedule B
4.	Purpose for which CPSE has been setup and the main business now	BIRAC is a Section 8 Not-for-profit Company under the Companies Act, 2013, a public sector undertaking, set up by Department of Biotechnology, Ministry of Science & Technology, Government of India as its interface agency to promote industry-academia interface. The mandate is to nurture and empower the biotech innovation ecosystem and transform all elements of the nascent biotechnology industry systems.
5.	Any capital restructuring during 2016-17, i.e., buy-back of shares, issue of bonus shares, issue of fresh shares, splitting of shares and percentage of PAT given as dividend	N.A.
6.	Whether shares are listed (if yes, name of the stock exchange and price of the share as on date)	No
7.	Any change in capacity during the year or next year (MoU year)	No
8.	Any business unit hived off or to be hived off or added or to be added during the year or next year (MoU year)	N.A.
9.	Brief about the sector in which the CPSE is operating and national and international environment, regulatory environment etc.	The establishment of BIRAC is one of its kind in the country especially as a Developmental agency that is completely focused on catalyzing transformation of the Indian biotech industry – an industry that has different challenges than other sectors such as IT as gestation period is longer and regulatory issues are of a different nature. BIRAC remains unique as an Indian experiment to boost the Indian biotech sector. There are no comparable pan-Indian public led agencies with the mandate, vision and mission of BIRAC. In the international context, while there are public led agencies that focus on supporting high technology innovation driven industries such as TEKES of Finland and VINNOVA of Sweden. These agencies focus on all areas of high technologies unlike BIRAC that is solely focused on biotechnology. Besides these agencies belong to developed countries which have significantly greater level of investment in overall R&D in S&T measured in unit of R&D investment as percentage of GDP. Given this current context at the national and international level in terms of R&D funding and further BIRAC being a unique organization, benchmarking of BIRAC would not be possible.

10.	Details of revival plan, if approved	N.A.		
11.	Any adverse comment by Statutory auditors and its impact on Revenue/ Profit/Loss/Assets/ Liabilities	NIL		
12.	Whether C&AG supplemented the comments of the Statutory Auditor. If not, give details alongwith impact			
13.	Number and Name of subsidiary companies along with amount invested and share in its profit during last five years	Separate sheet may be attached, if more than one subsidiary. Information may be separately given in respect of each subsidiary and aggregated (consolidated) also.		
	Year*	Name of subsidiary	Amount invested (Rs.)	Share in its profit (Rs.)
	2013-14	NA		
	2014-15			
	2015-16			
	2016-17			
	2017-18			
14.	Number and Name of Joint Venture companies along with amount invested and share in its profit during last five years	Separate sheet may be attached, if more than one Joint Venture. Information may be separately given in respect of each Joint Venture and aggregated (consolidated) also.		
	Year*	Name of Joint Venture	Amount invested (Rs.)	Share in its profit (Rs.)
	2013-14	NA		
	2014-15			
	2015-16			
	2016-17			
	2017-18			

IV PERFORMANCE ASSESSMENT TARGETS AND THEIR DETERMINATION

ANNEXURE –II, PART –B

Sl. No.	Parameter	Marks	2019-20 (Est.)	Best in 5 years	MoU Target (for the year 2020-21)				
					Excellent (1)	V. Good (2)	Good (3)	Fair (4)	Poor (5)
1	No. of beneficiaries supported during the year (No.)	10	550	419	725	690	650	620	600
2	Mobilization of resources from other than DBT as a % of Annual allocation from DBT (%)	10	30	25	33	32	31	30	29
3	Number of projects getting fund from partnered funding (i.e. other than DBT) (No.)	10	27	16	29	28	27	26	25
4	Number of incubates who have been incubated in bio-incubation system of BIRAC during the year (No.)	10	530	359	650	640	630	620	610
5	Projects achieving Technology Readiness Level – 7 (TRL-7) During F.Y. 2020-21 (No.)	15	40	29	42	41	39	36	35
6	Product/ Technology ready for commercialization (TRL-8) (No.)	10	10	7	11	10	9	8	7
7	Technology and Products outlicensed/ commercialized (No.)	15	15	12	16	15	14	13	12
8	Increase in revenue generated as a % of administrative and office expenses over previous year (%)	10	—	—	100	90	80	70	60
9	% of TRL-3 projects from academia ready for validation by industry (%)	5	84	—	88	84	76	74	72

10	MoU parameter related to Gem: Percentage of Procurement of goods and services through GeM portal to total procurement of goods and services during the previous year i.e. FY 2019-20 (%)	5	—	—	25	20	15	10	5
----	--	---	---	---	----	----	----	----	---

1. In working out achievements for the year, quantified qualifications of CAG / Statutory Auditors would be adjusted in case of overstatement of Revenue/ Profit/ Surplus or understatement of Loss/ Deficit in addition to the negative marks prescribed in MoU guidelines.
2. Adjustment would be made in the Targets in case of improvement in actual performance over the estimated performance in the base year (2019-20) as per MoU Guidelines.
3. It was agreed that targets decided are unconditional and no offset will be allowed on any ground. Further evaluation would be subject to compliance of Additional Eligibility criteria as contained in MoU guidelines.

**For Biotechnology Industry Research
Assistance Council**

Sd/-
Mrs. Anju Bhalla
Managing Director
BIRAC
Date : 26.11.2020

For Ministry of Science & Technology

Sd/-
Dr. Renu Swarup
Secretary
Department of Biotechnology
Date : 26.11.2020

V Self-declaration/Certification by CPSE

It is hereby certified that the targets/ actual achievements in respect of MoU parameters have been worked out as per MOU Guidelines by adopting the norms and definitions laid down in MoU Guidelines for the year 2020 -21. In case, any deviation is found at any point of time, DPE is free to evaluate the performance as per MoU Guidelines. CPSE has no right of claim in this regard.

**Sd/-
Managing Director
Date : 26.11.2020**





Biotechnology Industry Research Assistance Council

(A Govt. of India Enterprise)

CIN NO: U73100DL2012NPL233152

1st Floor, MTNL Building, 9 CGO Complex, Lodhi Road, New Delhi-110003

Email : birac.dbt@nic.in, Website : www.birac.nic.in, Twitter handle @birac_2012